Category: BioTech

Biotech Finance News
BioTech, Finance

Halozyme’s Clinical Hold Lifted by FDA : Biotech

Halozyme Therapeutics, Inc (HALO) announced that the FDA has lifted the clinical hold from a phase Ib/II study (Study S1313). The study is evaluating PEGPH20 (PEGylated recombinant human hyaluronidase) in combination with a modified FOLFIRINOX chemotherapy (mFOLFIRINOX) in patients suffering from metastatic pancreatic adenocarcinoma. The Study S1313, which is being sponsored and conducted by SWOG (a cancer research cooperative group funded primarily by the National … Continue reading Halozyme’s Clinical Hold Lifted by FDA : Biotech

Richard Atkins
Analysis, BioTech, Diversified Tech, Finance, Mergers & Acquisitions, Semiconductors, Services Sector, Software, Tech IPO, Venture Capital

GPC Misses Street EPS Estimate

Genuine Parts Company reported earnings per share of $1.17, $0.04 less than the Street consensus but $0.09 better than year-ago EPS. The Street was expecting better performance from Genuine Parts’ office products and electrical wholesale operations. With the automotive group performing well and our expectation that the industrial and electrical/electronic (EIS) groups should improve as the year progresses, plus the accretion from the Exego acquisition, … Continue reading GPC Misses Street EPS Estimate

Jason KnoxLeave a comment
Analysis, BioTech, Diversified Tech, Finance, Mergers & Acquisitions, Semiconductors, Services Sector, Software, Tech IPO, Venture Capital

FWRD 2Q Consolidated Revenue Increased

Forward Air’s FWRD second-quarter consolidated revenue increased 8% but was roughly flat when excluding the addition of TQI, which was acquired in March. The core airport-to-airport business fell 5% from last year, driven by 3% deterioration in total yield and a low-single-digit fall in tonnage. A large portion of the revenue decline relates to a previously announced customer loss ($6 million impact). Forward Air Solutions … Continue reading FWRD 2Q Consolidated Revenue Increased

Jason KnoxLeave a comment
Analysis, BioTech, Commodities, Diversified Tech, Finance, Mergers & Acquisitions, Semiconductors, Services Sector, Software, Tech IPO, Venture Capital

STO Second Quarter Production Has Modest Rise

Santos’s second-quarter production rose 2% to 12.4 million barrels of oil equivalent (mmboe), marginally below expectations, and full-year 2013 production guidance has been reduced by 3% to between 52 and 55 mmboe. The decline reflects deferred oil and gas production from Chim Sao in Vietnam due to power system constraints, steeper than- expected natural field decline at Sangu, and deferred Carnarvon production due to poor … Continue reading STO Second Quarter Production Has Modest Rise

Ryan HoltzLeave a comment
BioTech, Finance

Halozyme Therapeutics, Inc (HALO) announced that the FDA has lifted the clinical hold from a phase Ib/II study (Study S1313). The study is evaluating PEGPH20 (PEGylated recombinant human hyaluronidase) in combination with a modified FOLFIRINOX chemotherapy (mFOLFIRINOX) in patients suffering from metastatic pancreatic adenocarcinoma. The Study S1313, which is being sponsored and conducted by SWOG (a cancer research cooperative group funded primarily by the National … Continue reading

Richard Atkins
BioTech, Finance

Major Biotech Stock in News: Amgen Files Blinatumomab Marketing Application

Amgen (AMGN) announced that it has submitted a Biologics License Application (BLA) to the FDA for its oncology candidate, blinatumomab. The company is looking to get the candidate approved for the treatment of adults suffering from Philadelphia-negative (Ph-) relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL). The BLA includes positive data from a phase II study which evaluated the use of blinatumomab in adults with Ph- relapsed/refractory … Continue reading Major Biotech Stock in News: Amgen Files Blinatumomab Marketing Application

Richard Atkins